Thyrotoxicosis secondary to thyroiditis following SARS-CoV-2 infection

Ankia Coetzee\textsuperscript{a,b}, Raisa Bhikoo\textsuperscript{b, c}, Bianca Berndorff\textsuperscript{d}, Wilhelmina Conradie\textsuperscript{d}, Jantjie J Taljaard\textsuperscript{b} and Marli Conradie-Smit\textsuperscript{a,b}

\textsuperscript{a}Division of Endocrinology and Metabolism, Stellenbosch University, Cape Town, South Africa
\textsuperscript{b}Department of Medicine, Stellenbosch University, Cape Town, South Africa
\textsuperscript{c}Department of Medical Imaging and Clinical Oncology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
\textsuperscript{d}Department of Surgery, Stellenbosch University, Cape Town, South Africa

\*Correspondence: raisa3121@gmail.com

Subacute thyroiditis is a granulomatous inflammatory disorder often triggered by a preceding viral infection. Patients typically present with complaints of anterior neck pain associated with a tender enlarged thyroid gland. The coronaviruses have never before been implicated in the aetiology of subacute thyroiditis. It is postulated that the pathogenesis related to thyroid disease in Coronavirus disease 2019 (COVID-19) is multifactorial. Contributory factors include effects of the virus-related cytokine storm and direct action of the virus on SARS-CoV-2 receptors in the thyroid. This article further reviews the association between thyroiditis and COVID-19. The clinical characteristics, diagnostic workup and management of a patient who presented with subacute thyroiditis following COVID-19 are discussed. Furthermore, complications are entertained and suggestions for the management of thyroiditis following COVID-19 are provided.

Keywords: Coronavirus disease-2019 (Covid-19), de Quervain’s, SARS-CoV-2, sub-acute, viral thyroiditis

Introduction
De Quervain’s thyroiditis or subacute granulomatous thyroiditis is a rare inflammatory condition triggered by a viral infection that occurred 2–6 weeks earlier.\textsuperscript{1,2} Many viruses have been implicated in the development of thyroiditis, but prior to the current pandemic coronavirus infection has never been associated with clinical subacute thyroiditis.\textsuperscript{3} Single-cell RNA profiling of the angiotensin converting enzyme 2 receptor (SARS-CoV-2 receptor), has proposed multiple tissue cells as the potential targets of SARS-CoV-2.\textsuperscript{4} Subsequent analysis across 36 tissues revealed a rank list of candidate cells potentially vulnerable to SARS-CoV-2. The top targets are lung cells and macrophages, cardiomyocytes, adrenal gland stromal cells and lastly stromal cells in testis, ovary and thyroid.\textsuperscript{5} Thyroiditis following COVID-19 may be under-recognized and the complications overlooked if thyrotoxicosis is not considered.

Case presentation
A 53-year-old woman presented to the Endocrinology Department complaining of anterior neck pain and palpitations. Five weeks prior to this presentation she was diagnosed with SARS-CoV-2 following a mild upper respiratory tract infection (URTI) symptoms (postnasal drip, cough and fever). The URTI symptoms resolved completely 10 days after onset. In the second week of isolation for COVID-19, she developed anterior neck pain, which radiated to her right ear with concomitant low-grade fever. After completion of the 14-day isolation period, she consulted a general practitioner and was prescribed antibiotics. The symptoms persisted for another week and she experienced new onset palpitations. On reconsultation, four weeks after the COVID-19 diagnosis, thyroid function testing revealed thyrotoxicosis (Table 1). A beta blocker (bisoprolol) and prednisone were prescribed. The patient consulted our division querying the utility of prednisone 25 mg daily, etoricoxib 90 mg daily and propranolol 10 mg 6 hourly, as needed. Aspirin (75 mg daily) was also given. Six weeks after the COVID-19 diagnosis and 4 weeks after presenting with thyrotoxic symptoms, the patient was asymptomatic. The FT4 concentration had improved to just above the upper limit of normal (Table 1). The FT3 and CRP had now normalised. Furthermore, she was noted to be apyrexial with warm peripheries and a very fine tremor. There were no features of URTI. Pathognomonic features of Graves’ disease were absent. The thyroid gland was minimally enlarged and slightly tender to touch. The rest of the physical examination was unremarkable. The clinical impression was in keeping with de Quervain’s thyroiditis or subacute thyroiditis with mild thyrotoxicosis.

Thyroid scintigraphy (Figure 1) demonstrated no radiotracer uptake, in keeping with thyroiditis. Thyroid ultrasound (Figure 2a and b) revealed bilateral patchy hypoechoic areas with normal vascularity. Sub-centimetre colloid cysts and small reactive lymph nodes were also noted, in keeping with the clinical diagnosis.

Treatment
Pharmacological management was initiated with prednisone 25 mg daily, etoricoxib 90 mg daily and propranolol 10 mg 6 hourly, as needed. Aspirin (75 mg daily) was also given. Six weeks after the COVID-19 diagnosis and 4 weeks after presenting with thyrotoxic symptoms, the patient was asymptomatic. The FT4 concentration had improved to just above the upper limit of normal (Table 1). The FT3 and CRP had now normalised.

Discussion
The differential diagnoses for painful thyroiditis include subacute post-viral thyroiditis or de Quervain’s thyroiditis, acute suppurative thyroiditis and painful Hashimoto’s thyroiditis. Acute suppurative thyroiditis is a medical emergency that may lead...
to airway compromise. It usually follows a procedural intervention (e.g. fine needle aspiration), does not cause thyrotoxicosis per se, and appears as an abscess on ultrasound. Hashimoto’s thyroiditis is usually painless, mostly affects women and infrequently presents with thyrotoxicosis. A rare variant of painful Hashimoto’s has been described but, contrary to our patient, painful Hashimoto’s typically features an elevated serum level of thyroid antibodies (antithyroperoxidase or antithyroglobulin). Thyrotoxicosis in subacute thyroiditis is the result of the destruction of thyroid follicles and the release of thyroid hormones, as opposed to increased production of FT3 and FT4 as seen in Graves’ disease. The destruction of thyroid follicles is represented by the absence of uptake on the thyroid scintigram in our patient.

Thyroid scintigraphy is an important imaging modality in the evaluation of thyrotoxic patients and allows for the differentiation of hyperthyroidism from other causes of thyrotoxicosis. In cases of Graves’ disease, or nodular thyroid disease with autonomous function, various patterns of increased uptake are seen. In the early thyrotoxic phase of subacute thyroiditis, decreased or absent uptake is observed. It can be confirmed semi-quantitatively by calculating the percentage of thyroid uptake. Differential diagnoses to consider with decreased or absent thyroid uptake in the context of thyrotoxicosis include other types of thyroiditis (subacute thyroiditis, amiodarone-induced thyroiditis, acute thyroiditis), iatrogenic or factitious thyrotoxicosis (due to exogenous thyroxine) and ectopic hyper-functioning thyroid tissue. The role of thyroid ultrasound in diffusely enlarged thyroid glands is to exclude pathology undetectable on clinical examination and, in the case of a painful gland, the exclusion of suppurrative thyroiditis. It also enables fine-needle aspiration if malignancy is suspected. The characteristics in subacute thyroiditis include patchy poorly circumscribed hypoechoic areas with decreased vascularity on doppler.

Table 1: Serial symptoms, biochemistry and intervention following COVID-19 symptom onset

| Symptoms | Day 0 | 10 days | 2 weeks | 4 weeks | 5 weeks | 6 weeks |
|----------|-------|---------|---------|---------|---------|---------|
| URTI symptoms present COVID-19+ | | | | |
| Resolution of URTI symptoms | | | | |
| Anterior neck pain and palpitations Re-consultation | | | | |
| Anterior neck pain and palpitations improving | | | |
| Steroids initiated | | | |
| Anterior neck pain and palpitations resolved | | | |

Management

| FT4 (pmol/l) | 49.1 | 36.5 | 27.6 | 12–22.0 |
| FT3 (pmol/l) | < 0.01 | 5.3 | 3.1–6.8 |
| TSH (mIU/l) | Not done | < 0.01 | 0.27–4.20 |
| CRP (mg/l) | 68.4 | 13 | 2 | < 10 |
| ESR (mm/hr) | Not done | 30 | Not done | 0–10 |

Figure 1: The Tc-99m thyroid scintigram showed no uptake in the expected position of the thyroid, whereas the salivary gland uptake had normal uptake. This was done four weeks after COVID-19 diagnosis.

Figure 2: Thyroid ultrasound. IC = internal carotid, T = trachea, NT = normal thyroid. Figure 2a depicts bilateral colloid cysts in a heterogeneous thyroid gland, and hypoechoic nodular areas, specifically in the left lobe (see arrow). In 2b, vascularity is shown, which is not increased.

Thyrotoxicosis secondary to thyroiditis following SARS-CoV-2 infection
correlation is of utmost importance. Most changes normalise after one year, but nodular change might persist.\textsuperscript{15}

Subacute thyroiditis of viral origin is usually self-limited, and pain and fever resolve spontaneously after a period of 8–16 weeks.\textsuperscript{12} Normalisation of FT4 and FT3 levels parallels the resolution of the pain. Treatment is supportive and intended to reduce inflammation and symptoms.\textsuperscript{15} The clinical course can, however, vary, and whilst transient hypothyroidism is the norm, some patients develop permanent hypothyroidism irrespective of medical intervention.\textsuperscript{13} Little is known about the clinical course and outcomes of subacute thyroiditis following COVID-19. Brancatella et al. described typical clinical features in a case series, with resolution at six weeks and thyroid function either normalised or subclinical hypothyroidism present.\textsuperscript{14}

The prevalence of thyroiditis following COVID-19 infection is still to be elucidated as more knowledge is gained. A single-centre study retrospectively assessed thyroid function tests performed in 287 patients hospitalised for COVID-19, based on the hypothesis that the cytokine storm associated with COVID-19 may influence the thyroid function tests and/or that SARS-CoV-2 may directly act on thyroid cells. One in five patients (20.2\%) were found to have thyrotoxicosis and it was significantly associated with higher pro-inflammatory marker (interleukin-6) levels (odds ratio: 3.25, 95\% confidence interval 1.97–5.36; \(p < 0.001\)), supporting an indirect immune-modulated pathogenesis.\textsuperscript{15} The high prevalence of thyrotoxicosis in this study also suggests a possible causal relationship between COVID-19 and abnormal thyroid function.

Hyperthyroidism is associated with a hypercoagulable state through various mechanisms including alteration in synthesis and action of coagulation factors, effects on platelet maturation and function, an alteration in blood viscosity and effect on endothelial function.\textsuperscript{15–17} Furthermore, in addition to the effect of the circulating thyroid hormones, there may be immunological abnormalities contributing to the hypercoagulable state.\textsuperscript{16} Though many questions remain, COVID-19 has also been associated with a systemic coagulopathy and an acquired thrombophilia, with platelets uniquely produced by extramedullary megakaryocytes. Pathologists have recognised macro- and microvascular platelet-fibrin microthrombi in post-mortem studies.\textsuperscript{16} In hospitalised COVID-19 patients, prothrombinic states of low molecular weight heparin (LMWH) are commonly advocated, pending the outcome of ongoing trials on higher doses, antiplatelet agents and other anticoagulants such as rivaroxaban.\textsuperscript{19,20} A clear temporal association for thromboembolic disease following systemic glucocorticoid use has also been demonstrated.\textsuperscript{21} These factors formed the basis of aspirin in addition to glucocorticoids in our patient.

The full extent of post-COVID-19 related inflammatory manifestations still need to be described. Whether systemic manifestations, including thyroiditis, can be classified under the umbrella of a multisystemic inflammatory syndrome is still to be elucidated. As knowledge is gained regarding COVID-19 and thyroid disease, a causal relationship should be contemplated and guidance for optimal treatment and future care provided.

**Key learning points**

1. Thyroid involvement following SARS-CoV-2 infection is increasingly being reported.

2. Clinicians need to be aware of the association of COVID-19 related thyroid disease and maintain a high index of suspicion in the right clinical context.

3. Management should focus on both the acute and long-term complications of subacute thyroiditis, namely hypercoagulability and variable hypothyroidism.

4. Surveillance of patients with COVID-19 related thyroiditis should be prioritised to inform future care.

**Declaration of originality**

This paper has not been published or submitted for publication elsewhere.

**Declaration of authorship**

All authors have contributed significantly and in keeping with the latest guidelines of the International Committee of Medical Journal Editors. All authors are in agreement with the content of the manuscript and accept full responsibility for the content of the manuscript.

**Disclosure statement** – No potential conflict of interest was reported by the authors.

**ORCID**

Ankia Coetzee \textsuperscript{1} https://orcid.org/0000-0001-9993-6439

Raisa Bhikoo \textsuperscript{2} https://orcid.org/0000-0002-9913-8792

Bianca Berndorfier \textsuperscript{1} https://orcid.org/0000-0002-9165-9876

Wilhelmina Conradie \textsuperscript{1} https://orcid.org/0000-0002-9220-331X

Marli Conradie-Smit \textsuperscript{1} https://orcid.org/0000-0002-4252-6647

**References**

1. Fatourechi V, Aniszewski JP, Fatourechi GZE, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. *J Clin Endocrinol Metab*. 2003;88:2100–5. https://doi.org/10.1210/jc.2002-021799

2. Stasiak M, Michalak R, Stasiak B, et al. Clinical characteristics of subacute thyroiditis is different than it used to be – current state based on 15 years original material. *Neuroendocrinol Lett*. 2018;39:101–7.

3. Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after sars-Cov-2 infection. *J Clin Endocrinol Metab*. 2020;105:2367–70. https://doi.org/10.1210/clinem/dgaa276

4. Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty*. 2020;9:45. https://doi.org/10.1186/s40618-017-0655-5

5. Zhou L, Niu Z, Jiang X, et al. Systemic analysis of tissue cells potentially vulnerable to sars-Cov-2 infection by the protein-proofed single-cell RNA profiling of Ace2, Tmprss2 and furin proteases. *SSRN Electron J*. 2020. (preprint) https://doi.org/10.1101/2020.04.06.028522

6. Yediia N, Pirela D, Manzano A, et al. Thyroid abscess: challenges in diagnosis and management. *J Investig Med High Impact Case Reports*. 2018;6 (epub). https://doi.org/10.1177/2324709618778709

7. Rotondi M, Capelli V, Locantore P, et al. Painful Hashimoto’s thyroiditis: myth or reality? *J Endocrinol Invest*. 2017;40:815–8. https://doi.org/10.1007/s40618-017-0655-5

8. Mettler FA Jr., Guiberteau MJ. Essentials of nuclear medicine and molecular imaging. Elsevier. 2019. https://doi.org/10.1016/C2016-0-00043-8

9. Intenzo CM, DePapp AE, Jabbour S, et al. Scintigraphic manifestations of thyrotoxicosis. *Radiographics*. 2003;23:857–69. https://doi.org/10.1148/radiographics.234025716

10. Frates MC, Marqusee E, Benson CB, et al. Subacute granulomatous (De Quervain) thyroiditis: grayscale and Color Doppler sonographic characteristics. *J Ultrasound Med*. 2013;32:505–11. https://doi.org/10.7863/jum.2013.32.3.505

11. Lee YJ, Kim DW. Sonographic characteristics and interval changes of subacute thyroiditis. *J Ultrasound Med*. 2016;35:1653–59. https://doi.org/10.7863/ultra.15.09049
12. Zhao N, Wang S, Cui XJ, et al. Two-years prospective follow-up study of subacute thyroiditis. *Front Endocrinol (Lausanne)*. 2020;11:47. https://doi.org/10.3389/fendo.2020.00047
13. Sato J, Uchida T, Komiya K, et al. Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis. *Endocrine*. 2017;55:209–14. https://doi.org/10.1007/s12020-016-1122-3
14. Brancatella A, Ricci D, Cappellani D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. *J Clin Endocrinol Metab*. 2020;105:e3742–e6. https://doi.org/10.1210/clinem/dgaas37
15. Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. *Eur J Endocrinol*. 2020;183:381–7. https://doi.org/10.1530/EJE-20-0335
16. Squizzato A, Romualdi E, Büller HR, et al. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. *J Clin Endocrinol Metab*. 2007;92:2415–20. https://doi.org/10.1210/jc.2007-0199
17. Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. *Int J Endocrinol Metab*. 2017;15(3):e44157. https://doi.org/10.5812/ijjem.44157
18. Homoncik M, Gessl A, Frlitsch A, et al. Altered platelet plug formation in hyperthyroidism and hypothyroidism. *J Clin Endocrinol Metab*. 2007;92:3006–12. https://doi.org/10.1210/jc.2006-2644
19. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis*. 2020;50:54–67. https://doi.org/10.1007/s11239-020-02134-3
20. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost*. 2020;18:1023–26. https://doi.org/10.1111/jth.14810
21. Johannesdottir SA, Horváth-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study. *JAMA Intern Med*. 2013;173(9):743–752. https://doi.org/10.1001/jamainternmed.2013.122

Received: 9-02-2021 Accepted: 26-02-2021